Instead, downstream indicators of effective tumour recognition and immune effector function, such as activated CD8+ cells expressing the protease GZMB inducing apoptosis in the target cell or ongoing tumour cell phagocytosis by CD68+ macrophages might be of more value in determining the prognosis of CRC patients. This evidence concerns the gene CD8A and colorectal carcinoma.